Humacyte, Inc. (HUMA)
NASDAQ (NGS) NASDAQ (NGS) Primary 
All You Need to Know About Humacyte, Inc. (HUMA) Rating Upgrade to Buy
Humacyte, Inc. (HUMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Humacyte, Inc. (HUMA) Ascends But Remains Behind Market: Some Facts to Note
Humacyte, Inc. (HUMA) reachead $1.48 at the closing of the latest trading day, reflecting a +0.68% change compared to its last close.
Humacyte, Inc. (HUMA) Increases Despite Market Slip: Here's What You Need to Know
Humacyte, Inc. (HUMA) reachead $1.55 at the closing of the latest trading day, reflecting a +0.65% change compared to its last close.
Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call Transcript
Humacyte, Inc. (NASDAQ:HUMA ) Q4 2024 Earnings Conference Call March 27, 2025 8:30 AM ET Company Participants Thomas Johnson - Director, Corporate Communications, LifeSci Advisors, IR Laura Niklason - President and CEO Dale Sander - CFO and Chief Corporate Development Officer Conference Call Participants Josh Jennings - TD Cowen & Company Ryan Zimmerman - BTIG Vernon Bernardino - H.C. Wainwright Bruce Jackson - Benchmark Company Operator Good morning, ladies and gentlemen.
Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Humacyte, Inc. (HUMA) Flat As Market Gains: What You Should Know
In the closing of the recent trading day, Humacyte, Inc. (HUMA) stood at $3.32, denoting no change from the preceding trading day.
Wall Street Bulls Look Optimistic About Humacyte, Inc. (HUMA): Should You Buy?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade
Humacyte, Inc. (HUMA) closed the most recent trading day at $3.15, moving -1.56% from the previous trading session.
Humacyte, Inc. (HUMA) Falls More Steeply Than Broader Market: What Investors Need to Know
In the most recent trading session, Humacyte, Inc. (HUMA) closed at $3.37, indicating a -1.75% shift from the previous trading day.
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights
Humacyte, Inc. (HUMA) closed the most recent trading day at $3.96, moving -1.25% from the previous trading session.
Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why
Humacyte, Inc. (HUMA) concluded the recent trading session at $4.37, signifying a +1.63% move from its prior day's close.
Shareholders that Lost Money on Humacyte, Inc. (HUMA) Should Contact Levi & Korsinsky about Pending Class Action - HUMA
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
